Oligoastrocytoma
What's New
Last Posted: May 22, 2023
- Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.
Kwanghoon Lee, et al. Scientific reports 2023 0 (1) 6761 - Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.
Zetterling Maria, et al. PloS one 2017 0 (11) e0188419 - High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients.
Wu Zijun, et al. Frontiers in cell and developmental biology 2021 0 679684 - Prognostic Role of EYA4 in Lower Grade Glioma with IDH1 Mutation and 1p19q Co-Deletion.
Zhu Jin, et al. World neurosurgery 2021 0 e1174-e1179 - Allergy may confer better survival on patients with gliomas.
Lehrer Steven, et al. Clinical neurology and neurosurgery 2019 0 63-67 - Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki Keisuke, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2002 0 (1) 196-201 - Subtyping and grading of lower-grade gliomas using integrated feature selection and support vector machine.
Munquad Sana et al. Briefings in functional genomics 2022 - Engrailed 1 overexpression as a potential prognostic marker in Lower Grade Glioma.
Zhu Jin, et al. PeerJ 2019 0 e7414 - von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53.
Lehrer Steven, et al. Brain tumor research and treatment 2019 4 (1) 33-38 - Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan K S, et al. Journal of clinical pathology 2016 1 - Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene.
Lhotska Halka, et al. Genes, chromosomes & cancer 2015 11 (11) 655-67 - IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper Heather E, et al. Oncotarget 2015 7 - IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil.
Pessôa I A, et al. Genetics and molecular research : GMR 2015 0 (2) 6533-42 - Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura Ryosuke, et al. Neuropathology : official journal of the Japanese Society of Neuropathology 2015 8 (4) 324-35 - Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Das Bibhu Ranjan, et al. Asian Pacific journal of cancer prevention : APJCP 2013 0 (12) 7261-4 - Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.
Zhang Chuan-Bao, et al. Journal of cancer research and clinical oncology 2014 1 (1) 45-51 - An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska Marzena Anna, et al. Molecular diagnosis & therapy 2014 2 (1) 45-53 - [Relationship between IDH1 mutation and clinic pathologic features in human supratentorial WHO grade II gliomas].
Tang Jun-Jia, et al. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 2013 1 (1) 60-3 - 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H, et al. Neuro-oncology 2013 3 - Molecular markers in low-grade gliomas: predictive or prognostic?
Hartmann Christian, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 7 (13) 4588-99
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 21, 2024
- Content source: